Log in to your Inderes Free account to see all free content on this page.
Diamyd Medical
18.48
SEK
+2.67 %
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+2.67%
+12.41%
+22.87%
+31.62%
+31.06%
+160.65%
+24.52%
+3.77%
+512.59%
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Read moreMarket cap
1.92B SEK
Turnover
8.27M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
29.1.
2025
Interim report Q1'25
9.4.
2025
Interim report Q2'25
25.6.
2025
Interim report Q3'25
ShowingAll content types
Diamyd Medical AB: Renowned Diabetes Investigator, Emily Sims, Joins Diamyd Medical's Scientific Advisory Board
Diamyd Medical AB: Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio